April 16, 2025

CONSORT 2025: Setting New Standards for Clinical Trial Reporting

"Readers should not have to infer what was probably done; they should be told explicitly." This principle drives the comprehensive CONSORT 2025 update, with its 7 new checklist items aimed at improving clinical trial transparency.

Conexiant

April 09, 2025

Study: Langerhans Cells Key to Diagnosing Contact Dermatitis

A case-control study of 170 biopsied dermatitis cases found that Langerhans cell collections were significantly more common in allergic contact dermatitis than in nonallergic cases.

Conexiant

April 08, 2025

Biomarkers Identified in Steroid Withdrawal

Distinct clinical and molecular features of topical steroid withdrawal, identifying potential therapeutic targets and diagnostic criteria.

Conexiant

April 08, 2025

Burn Scar Study Shows Laser Benefits

Fractional CO₂ laser therapy improves vascularity, pigmentation, and pliability in hypertrophic burn scars among patients with skin of color.

Conexiant

March 31, 2025

Tariff Threat: Drugs Could Cost U.S. $750M More

New research reveals 25% tariffs on Canadian pharmaceuticals would impact critical medications, strain supply chains, and potentially increase costs—with 28 drugs having no alternative suppliers.

Conexiant

March 21, 2025

Biosimilars Match Adalimumab Originator Efficacy for Psoriasis

Amjevita and Imraldi were as effective as Humira for both new starters and patients switching from Humira, researchers concluded

Conexiant

March 19, 2025

Study: Sex Differences in Physician Suicide

Researchers found that female physicians had a significantly higher suicide risk than female nonphysicians.

Conexiant

July 31, 2024

Alopecia Areata Linked to Mental, Autoimmune Risks

New study published in JAMA Dermatology reveals that patients newly diagnosed with alopecia areata face a higher risk of developing psychiatric and autoimmune disorders.

Conexiant

January 15, 2025

Bertagnolli to Exit NIH Director Role

NIH director, Dr. Monica M. Bertagnolli, is stepping down after launching major initiatives in women's health and long COVID research, indicating optimism for their continuation under new leadership.

Conexiant